Recombinant Human PRAME protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PRAME also known as Preferentially Expressed Antigen in Melanoma is a protein typically weighing around 50 kDa. It is found mostly in testis tissue but also appears in several types of tumors including melanoma and some leukemias. PRAME does not show significant expression in most normal tissues making it a potential target for cancer therapies. Immunohistochemistry (IHC) techniques such as PRAME IHC and PRAME staining often use monoclonal antibodies like mAb EPR20330 to detect PRAME protein presence in various samples.

Biological function summary

PRAME acts as a repressor of retinoic acid signaling a process important for cell differentiation and growth. It does not directly form part of a complex but interacts with components involved in retinoic acid pathways. By binding to retinoic acid receptor complexes PRAME prevents activation of genes involved in cell cycle arrest and apoptosis contributing to unchecked cellular proliferation seen in certain cancers.

Pathways

PRAME participates in the retinoic acid and various oncogenic signaling processes. It influences the retinoic acid pathway by interfering with the retinoic acid receptor (RAR) signaling. This interference with key proteins like RAR disrupts the normal regulatory processes that typically inhibit cancer progression. PRAME's modulation of these pathways highlights its role in promoting tumor growth and survival.

PRAME has significant relevance to cancer particularly melanoma. It is often used as a biomarker for melanoma identification due to its overexpression in such tumors. Additionally PRAME's connection to acute myeloid leukemia (AML) emerges from its ability to act similarly in diverse malignant cells. In these diseases the overexpression of PRAME interferes with normal differentiation processes and allows for sustained proliferation of malignant cells suggesting its potential role as a therapeutic target or diagnostic marker in oncology.